ZBIO

ProShares UltraPro Short Nasdaq Biotechnology

ZBIO Fund Description

The ProShares UltraPro NASDAQ Biotechnology provides -3x daily exposure to a market-cap-weighted index of biotechnology and pharmaceutical companies listed on the NASDAQ.

ZBIO Factset Analytics Insight

ZBIO is the newest inverse play on the NASDAQ Biotechnology Index, this one being -3x the exposure of the daily gains of the index, as opposed to the relatively successful -2x iteration of sister fund BIS. The fund gains its -3x exposure to the index through swap agreements, and rebalances its exposure daily. ZBIO is the second triple-inverse biotech fund, following hot on the heels of Direxion’s LABD, which was launched a month earlier. Like all geared funds that rebalance daily, ZBIO is meant for short-term trading, since compounding effects over the long term could create vast differences from expected returns relative to the index—for good or for ill. Trade this fund with limit orders.

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
COMPARE
RESET
Select ETFs to compare their performance:
Bats Book Viewer
TOP OF BOOK
SHARES/SIZEPRICE
ASKS----
----
----
----
----
BIDS----
----
----
----
----
LAST 10 TRADES
TIMEPRICESHARES
------
------
------
------
------
------
------
------
------
------
Bats BZX Real-time Quote - 23:59:59
Daily Spread
Premium/Discount
Volume

ZBIO Factset Analytics Block Liquidity

As of 11/22/17
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of ZBIO. ZBIO is rated a N/A out of 5.

ZBIO Summary Data

ProShares
06/23/15
Open-Ended Fund
0.95%
$5.68M
0.48%

ZBIO Portfolio Data

0.00%
12/26/17

ZBIO Index Data

Market Cap
NASDAQ - Listed
N/A

ZBIO Fund Structure

Yes
No
No Policy
N/A
N/A
High
-3
Daily

ZBIO Tax Exposures

20% / 39.6%
--
No

ZBIO Tradability

24,526
$284.77K
15,542
$163.46K
0.48%
0.00%
1.14% / -1.08%
None
50,000
0.31
0.04%
511
$12.66
N/A